Mumbai, India, and Naples, Florida, USA, November 2, 2026
Lupin Limited, a global pharmaceutical company, has announced that it has received U.S. Food and Drug Administration (FDA) approval for its Abbreviated New Drug Applications (ANDAs) for Amifampridine Tablets, 10 mg. This regulatory milestone strengthens the company’s presence in the U.S. generic pharmaceutical market and expands its portfolio of treatments for rare neurological disorders. The approved tablets are bioequivalent to the reference listed drug (RLD), Firdapse® (amifampridine) Tablets, 10 mg, developed by Catalyst Pharmaceuticals, Inc. Lupin is among the first applicants to receive approval for the generic product and is eligible for 180 days of shared generic drug exclusivity. The approval represents an important development in the company’s complex generic and specialty pharmaceutical business, highlighting its continued focus on bringing additional treatment options to patients in the United States. Amifampridine is an important medication used in the management of Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune neuromuscular disorder that affects communication between nerves and muscles. The regulatory achievement also reflects Lupin’s ongoing efforts to expand access to established therapies through the development and commercialization of high-quality generic medicines.
FDA Approval Strengthens Lupin’s Generic Drug Portfolio
The U.S. FDA approval of Amifampridine Tablets, 10 mg, marks another important regulatory achievement for Lupin in the competitive U.S. pharmaceutical market. The approval was granted through the ANDA pathway, which allows pharmaceutical manufacturers to develop generic versions of previously approved reference medicines by demonstrating the required pharmaceutical equivalence and bioequivalence standards. Lupin’s product has been confirmed as bioequivalent to Firdapse® Tablets, 10 mg, marketed by Catalyst Pharmaceuticals. Bioequivalence is a critical regulatory requirement for generic medicines because it establishes that the generic product delivers the active pharmaceutical ingredient at a comparable rate and extent of absorption to the reference product under appropriate study conditions. The approval demonstrates Lupin’s progress in developing generic formulations that meet U.S. regulatory requirements for quality, safety and performance. As one of the first ANDA applicants, Lupin is eligible for 180 days of shared generic exclusivity, an important commercial provision associated with certain first generic approvals. This exclusivity can provide an opportunity for qualifying applicants to establish their position in the U.S. generic market during the applicable period. The milestone further supports Lupin’s strategy of expanding its specialty and complex generic medicine offerings across important therapeutic areas.
Amifampridine Targets Rare Neuromuscular Disorder LEMS
Amifampridine is used to treat Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder that interferes with communication between nerves and muscles. In people with LEMS, the immune system mistakenly attacks voltage-gated calcium channels at the nerve endings, reducing the release of acetylcholine, a chemical messenger required for normal muscle contraction. This disruption can result in muscle weakness, fatigue, difficulty walking and other functional challenges. Amifampridine works by blocking voltage-gated potassium channels in nerve cells, prolonging the electrical signal and increasing calcium entry into nerve endings. This mechanism helps promote the release of acetylcholine and improves communication between nerves and muscles. The treatment can help improve muscle strength and physical function in eligible patients. LEMS is an uncommon condition that may occur independently or in association with certain cancers, particularly small-cell lung cancer. Because of its rarity and complex disease mechanisms, access to established treatment options remains important for affected patients. The availability of an FDA-approved generic formulation may contribute to additional competition in the pharmaceutical market, although actual pricing, availability and patient access will depend on commercial launch arrangements and applicable regulatory and legal considerations.
Advertisement
Lupin Advances Its U.S. Pharmaceutical Market Presence
The latest approval reinforces Lupin’s commitment to expanding its pharmaceutical business in the United States through generic medicines, complex formulations and specialty therapies. Headquartered in Mumbai, India, Lupin has an international presence, with products distributed across more than 100 markets. Its pharmaceutical portfolio covers several major therapeutic areas, including cardiovascular diseases, respiratory disorders, diabetes, gastrointestinal conditions and women’s health. The company operates 15 manufacturing facilities and six research centers, supporting its product development, manufacturing and quality operations. The approval of Amifampridine Tablets adds another product to its U.S. regulatory portfolio and demonstrates the importance of regulatory compliance, pharmaceutical equivalence and bioequivalence in generic drug development. Lupin’s eligibility for shared generic exclusivity also represents a notable commercial opportunity in the specialty generic segment. However, the FDA approval announcement does not specify a commercial launch date. Overall, this development highlights the continuing role of pharmaceutical manufacturers in expanding generic treatment options for patients with rare and chronic conditions while strengthening their position in the global pharmaceutical market.
Source: Lupin Limited press release
